References

Unresolved reference

External reference

The clinical practice guidelines for the management of angiosarcoma of the scalp

2015 · External reference

In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice

10.2307/3579856 · 1998 · External reference

Comparison of expression profiles of several fibroblast growth factor receptors in the mouse jejunum: suggestive evidence for a differential radioprotective effect among major FGF family members and the potency of FGF1

10.1667/rr1570.1 · 2009 · External reference

Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life

10.1021/bi9927742 · 2000 · External reference

Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action

10.1016/j.jmb.2005.07.066 · 2005 · External reference

Increased protein stability of FGF1 can compensate for its reduced affinity for heparin

10.1074/jbc.m109.001289 · 2009 · External reference

Structural stability of human fibroblast growth factor-1 is essential for protective effects against radiation-induced intestinal damage

10.1016/j.ijrobp.2012.04.042 · 2013 · External reference

Fibroblast growth factor signalling: from development to cancer

10.1038/nrc2780 · 2010 · External reference

Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth

10.1158/0008-5472.can-06-3843 · 2007 · External reference

Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1)

10.1016/s0923-1811(97)00032-7 · 1998 · External reference

Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1, in vitro

10.1111/j.1349-7006.2011.02190.x · 2012 · External reference

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma

10.1158/1535-7163.mct-12-0893 · 2013 · External reference

FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition

10.1016/s0165-6147(00)01676-x · 2001 · External reference

FGF-dependent regulation of VEGF receptor 2 expression in mice

10.1172/jci44762 · 2011 · External reference

Inhibition of angiogenesis by a mouse Sprouty protein

10.1074/jbc.m006922200 · 2001 · External reference

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas

10.1200/jco.2008.20.4495 · 2009 · External reference

Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO)

10.1634/theoncologist.2011-0237 · 2012 · External reference

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

10.1093/annonc/mds237 · 2013 · External reference

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

10.1093/annonc/mdl962 · 2006 · External reference

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

10.1002/ijc.28187 · 2013 · External reference

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

10.1054/bjoc.2001.1936 · 2001 · External reference

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

10.1016/s0959-8049(02)00013-8 · 2002 · External reference

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents

10.1158/1541-7786.mcr-06-0404 · 2007 · External reference